Enfuvirtide (T-20): Potentials and Challenges

Journal of the Association of Nurses in AIDS Care

Volumn 15, Issue 6, 2004, Pages 65-71

  Foy, Karlissa ^a   Juethner, Salomé N ^a  

^a Community Research Initiative of New England in Boston ^*  (United Kingdom)

Author keywords

adverse event; enfuvirtide; HAART; injection site reactions; optimized background (OB) regimen

Indexed keywords

ENFUVIRTIDE; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; PEPTIDE FRAGMENT;

HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NURSING; PHASE 3 CLINICAL TRIAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL TRIALS, PHASE III; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; INJECTIONS, SUBCUTANEOUS; PEPTIDE FRAGMENTS;

EID: 16644395197     PISSN: 10553290     EISSN: None     Source Type: Journal    
DOI: 10.1177/1055329003256414     Document Type: Article

References (20)

1. Ball, R. & Kinchelow, T. (2003) Pathology of injection site reactions with enfuvirtide (T-20). Abstract 714. Tenth Conference on Retroviruses and Opportunistic Infections, Boston.
2. Bean P. HIV genetic mutations causing resistance to the new drug T-20: Recent findings. American Clinical Laboratory 21 8 (2002) 15-16
3. Boyd, M., Ruxrungtham K., Zhang X., Bellibas S. E., Buss N. E. & Patel, I. H. (2003) Enfuvirtide-investigations on the drug interaction potential in HIV-infected patients. Abstract 541. Tenth Conference on Retroviruses and Opportunistic Infections, Boston.
4. Chan D.C., Fass D., Berger J.M., and Kim P.S. Core structure of gp41 from the HIVenvelope glycoprotein. Cell 89 (1997) 263-273
5. Clotet, B., Lazzarin A., Cooper D., Reynes J., Arasteh K., Nelson M., et al (2002) Enfuvirtide (T-20) in combination with an optimized background (OB) regimen vs. OB alone in patients with prior experience or resistance to each of the three classes of approved antiretrovirals (ARVs) in Europe and Australia. Abstract LbOr19A. Fourteenth International Aids Conference, Barcelona, Spain.
6. Cohen C.J., Dusek A., Green J., Johns E.L., Nelson E., and Recny M.A. Long-term treatment with subcutaneous T-20, a fusion inhibitor, in HIV-infected patients: Patient satisfaction and impact on activities of daily living. AIDS Patient Care STDS 16 7 (2002) 327-335
7. Delfraissy, J-F., Montaner J., Eron J., DeMasi R., Chung J, Drobnes C., et al: (2003) Summary of pooled efficacy and safety analyses of enfuvirtide (ENF) treatment for 24 weeks in TORO 1 and TORO 2 Phase III trials in highly antiretroviral (ARV) treatment experienced patients. Abstract 568. Tenth Conference on Retroviruses and Opportunistic Infections, Boston.
8. Drobnes, C., Fang L., Nelson E., True A., Salgo M. & Delehanty, J. (2002) Tolerability of enfuvirtide (T-20) during chronic therapy in Phase II trials. Abstract 171. Forty-second Interscience Conference on Anti-microbial Agents and Chemotherapy, San Diego, CA.
9. Green, J., Wintfeld, N. (2002) Patients acceptance with selfinjection of enfuvirtide (T-20) for HIV over 24 weeks of treatment. Abstract P48. Sixth International Congress on Drug Therapy in HIV Infection, Glasgow, Scotland.
10. Greenberg, M. L., Melby T., Sista P., DeMasi R., Cammack N., Salgo M., et al: (2003), Baseline and on-treatment susceptibility to enfuvirtide seen in TORO 1 and TORO 2 to 24 weeks. Abstract 141. Tenth Conference on Retroviruses and Opportunistic Infections, Boston.
11. Henry, K., Lalezari J., OHearn M., Trottier B., Montaner J., Piliero P., et al: (2002) Enfuvirtide (T-20) in combination with an optimized background (OB) regimen vs. OB alone in patients with prior experience or resistance to each of the three classes of approved antiretrovirals (ARVs) in North America and Brazil. Abstract LbOr19B. Fourteenth International Aids Conference, Barcelona, Spain.
12. Hirschler B. (2003) Record high price set for new Roche AIDS drug. Retrieved from http://www.aidsmeds.com/news/20030224inds001.html
13. Hornberger, J. & Green, J. (2002) Modeling the clinical prognosis of patients receiving enfuvirtide (T-20) in combination with an optimized background regimen according to virological and immunological response after 24 weeks. Abstract P40. Sixth International Congress on Drug Therapy in HIV infection, Glasgow, Scotland.
14. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., and Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4+ receptor and a neutralizing antibody. Nature 393 (1998) 648-659
15. Lu J., Sista P., Cammack N., and Kuritzkes D. Fitness of HIV-1 clinical isolates resistant to T-20 (enfuvirtide). Antiviral Therapy 7 S56 (2002) Abstract 67
16. Raglow G.J., Luby S.P., and Nabi N. Therapeutic injections in Pakistan: From the patients'perspective. Tropical Medicine and International Health 6 1 (2001) 69-75
17. Roche Pharmaceutical. (2002, December 18). Update on the manufacture of new HIV drug, Fuzeon. Media release.
18. Starr-Spires L.D., and Collman R.G. HIV-1 entry and entry inhibitors as therapeutic agents. Clinics in Laboratory Medicine 22 (2002) 680-701
19. Vos J., Gumodoka B., van Asten H.A., Berege Z.A., Dolmans W.M., and Borgdorff M.W. Improved injection practices after the introduction of treatment and sterility guidelines in Tanzania. Tropical Medicine and International Health 3 4 (1998) 291-296
20. Wild C., Greenwell T., and Matthews T. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Research and Human Retroviruses 9 (1993) 1051-1053